Kulkarni R - Search Results

1

Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir.

Kulkarni R, Feng JY, Miller MD, White KL. Kulkarni R, et al. Antiviral Res. 2014 Jan;101:131-5. doi: 10.1016/j.antiviral.2013.11.010. Epub 2013 Nov 28. Antiviral Res. 2014. PMID: 24291780

2

The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.

Kulkarni R, Babaoglu K, Lansdon EB, Rimsky L, Van Eygen V, Picchio G, Svarovskaia E, Miller MD, White KL. Kulkarni R, et al. J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):47-54. doi: 10.1097/QAI.0b013e31823aca74. J Acquir Immune Defic Syndr. 2012. PMID: 21997204

3

Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).

Porter DP, Kulkarni R, Fralich T, Miller MD, White KL. Porter DP, et al. Among authors: kulkarni r. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):318-26. doi: 10.1097/QAI.0000000000000017. J Acquir Immune Defic Syndr. 2014. PMID: 24525469 Clinical Trial.

4

The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.

Kulkarni R, Hluhanich R, McColl DM, Miller MD, White KL. Kulkarni R, et al. Antimicrob Agents Chemother. 2014 Oct;58(10):6145-50. doi: 10.1128/AAC.03591-14. Epub 2014 Aug 4. Antimicrob Agents Chemother. 2014. PMID: 25092710 Free PMC article.

5

HIV-1 clinical isolates with the E138A substitution in reverse transcriptase show full susceptibility to emtricitabine and other nucleoside reverse transcriptase inhibitors.

Porter DP, Kulkarni R, White KL. Porter DP, et al. Among authors: kulkarni r. Antimicrob Agents Chemother. 2014 Sep;58(9):5640-1. doi: 10.1128/AAC.03173-14. Antimicrob Agents Chemother. 2014. PMID: 25125565 Free PMC article. No abstract available.

6

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.

White KL, Kulkarni R, McColl DJ, Rhee MS, Szwarcberg J, Cheng AK, Miller MD. White KL, et al. Among authors: kulkarni r. Antivir Ther. 2015;20(3):317-27. doi: 10.3851/IMP2885. Epub 2014 Oct 16. Antivir Ther. 2015. PMID: 25321623 Clinical Trial.

7

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.

Kulkarni R, Abram ME, McColl DJ, Barnes T, Fordyce MW, Szwarcberg J, Cheng AK, Miller MD, White KL. Kulkarni R, et al. HIV Clin Trials. 2014 Sep-Oct;15(5):218-30. doi: 10.1310/hct1505-218. HIV Clin Trials. 2014. PMID: 25350960 Clinical Trial.

8

Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients.

White K, Kulkarni R, Miller MD. White K, et al. Among authors: kulkarni r. J Antimicrob Chemother. 2015 Sep;70(9):2632-8. doi: 10.1093/jac/dkv149. Epub 2015 Jun 24. J Antimicrob Chemother. 2015. PMID: 26108607 Clinical Trial.

9

Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.

Porter DP, Toma J, Tan Y, Solberg O, Cai S, Kulkarni R, Andreatta K, Lie Y, Chuck SK, Palella F, Miller MD, White KL. Porter DP, et al. Among authors: kulkarni r. HIV Clin Trials. 2016 Feb;17(1):29-37. doi: 10.1080/15284336.2015.1115585. HIV Clin Trials. 2016. PMID: 26899540 Clinical Trial.

10

Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks.

Porter DP, Kulkarni R, Garner W, Miller MD, White KL. Porter DP, et al. Among authors: kulkarni r. Antivir Ther. 2017;22(6):495-502. doi: 10.3851/IMP3128. Epub 2017 Jan 16. Antivir Ther. 2017. PMID: 28091393 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,700 results

Search Page

Filters